The claim that CJC-1295 flattens growth hormone pulsatility is contradicted by the trial that measured it. Pulse frequency and magnitude were unchanged. What rose was the baseline between pulses, by 7.5-fold. That is a different concern than losing pulsatility, and a more accurate one.
Sermorelin and CJC-1295 are both GHRH analogs that stimulate the pituitary to release growth hormone. The entire practical difference is duration. Sermorelin clears in minutes and is dosed nightly. CJC-1295 with Drug Affinity Complex binds to albumin and has an estimated half-life of 5.8 to 8.1 days [1], which changes what the GH axis is exposed to and what the safety questions are.
- CJC-1295 with DAC: half-life 5.8 to 8.1 days. Sermorelin: roughly 4 minutes [1][3]
- A single CJC-1295 dose raised IGF-1 1.5 to 3-fold for 9 to 11 days [1]
- GH pulse frequency and magnitude were unchanged; basal GH rose 7.5-fold [2]
- FDA has identified serious adverse events with CJC-1295 including increased heart rate and systemic vasodilatory reaction [6]
- The only registered CJC-1295 patient trial was terminated in 2006 [5]
- No head-to-head trial of the two exists. Both are on the WADA Prohibited List [7]
The Structural Difference
Both are built on the same 29-amino-acid GHRH fragment. Sermorelin is that fragment unmodified, which is why it is cleared so quickly.
CJC-1295 is a tetrasubstituted form of hGRF(1-29) carrying an added maleimidopropionamide derivative of lysine at the C terminus, which bioconjugates to the free thiol on Cys34 of serum albumin [4]. Four amino acid substitutions resist enzymatic degradation, and the albumin binding is what produces the multi-day duration. Marketing sometimes enumerates the specific substitutions; the primary literature I could verify does not, so treat detailed substitution lists on vendor sites with caution.
CJC-1295 without DAC is widely sold and often equated with Mod GRF 1-29. That equivalence is vendor nomenclature rather than established terminology, and the no-DAC form remains essentially uncharacterized in the peer-reviewed human literature, with no controlled clinical studies evaluating it in humans. When a product is labeled CJC-1295, confirm which form is being dispensed.
Duration and Dosing
| Sermorelin | CJC-1295 with DAC | |
|---|---|---|
| Half-life | [About 4 minutes](https://pubmed.ncbi.nlm.nih.gov/7962295/) [3] | [5.8 to 8.1 days](https://pubmed.ncbi.nlm.nih.gov/16352683/) [1] |
| Typical dosing | Nightly, at bedtime | Weekly or less frequent |
| GH exposure pattern | Amplifies the natural nightly pulse | Sustained elevation between pulses [2] |
| Human trial base | Pediatric GHD, small adult studies | Three published human studies [1][2][8] |
| FDA approval | Withdrawn 2009, commercial reasons | Never approved |
| WADA status | Prohibited at all times [7] | Prohibited at all times [7] |
The dosing convenience is real and is the main reason patients ask about CJC-1295. Weekly injection is easier to sustain than nightly injection, and adherence matters over a 6-month protocol.
What CJC-1295 Actually Does to GH Release
In healthy adults, a single subcutaneous dose produced dose-dependent increases in mean plasma GH of 2 to 10-fold for 6 days or more, and increases in IGF-1 of 1.5 to 3-fold for 9 to 11 days [1]. With repeated dosing, mean IGF-1 remained above baseline for up to 28 days [1]. Those are substantial and sustained effects.
The pulsatility question deserves correction, because the common claim is wrong in a specific way. A study designed to test it found that one week after dosing, the frequency and magnitude of GH secretory pulses were unaltered, while basal GH rose 7.5-fold, mean GH rose 46%, and IGF-1 rose 45% [2].
CJC-1295 does not abolish pulsatility. Pulses continue at normal frequency and size. What changes is the trough between them, which no longer falls as low. Whether chronically elevated basal GH matters over years has not been established in humans, and it is a different question from the one usually asked.
Safety and the Terminated Trial
FDA has stated that it has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction, and that available clinical data are limited [6]. That is the agency's own assessment and it has no equivalent for sermorelin, which does not appear on that page.
The clinical development history is also short. The only registered patient trial, a Phase 2 study of CJC-1295 in HIV-associated visceral obesity [5], is recorded as terminated in 2006. The registry entry does not state a reason. Contemporaneous reporting attributed the halt to a participant death, with the cause under investigation at the time. No public record I could verify establishes a causal relationship to the drug, and specific accounts circulating online about the manner of death are not supported by the sources they cite. The defensible summary is that development stopped early and the safety question was never resolved publicly.
Regulatory Status of Each
Neither is an FDA-approved drug. Sermorelin held approval as Geref until the applications were withdrawn effective June 2009, and FDA determined the withdrawal was not for reasons of safety or effectiveness. CJC-1295 has never been approved.
On compounding status, CJC-1295 appears on FDA's bulk substances page under substances nominated but subsequently withdrawn by the nominator [6]. Sermorelin does not appear on that page at all. Both are named explicitly on the 2026 WADA Prohibited List under section S2.2.4, growth hormone releasing factors [7], prohibited at all times in and out of competition.
Which One Applies to You
No head-to-head trial has compared them, so any preference is an inference from separate studies rather than a measured result. What the evidence supports is a straightforward trade.
- Sermorelin: shorter human track record per dose but a dosing pattern that mirrors natural GH release, no FDA adverse event statement, and nightly administration
- CJC-1295: far more convenient dosing and larger sustained IGF-1 elevation, against an FDA adverse event statement, a terminated trial, and sustained basal GH whose long-term effect is unstudied
- The no-DAC form sold most widely has no controlled human studies at all
- Both require a baseline IGF-1 and a 90-day retest to be evaluated honestly
- Neither is an option for anyone subject to anti-doping testing [7]
Choosing sermorelin or CJC-1295 comes down to a baseline IGF-1 and how you dose, not a checkout page. SystemLabs tests IGF-1 before prescribing and formulates sermorelin and CJC-1295 on clinical indication, so the choice is built from your numbers.
Frequently Asked Questions
What is the difference between sermorelin and CJC-1295?
Duration, primarily. Both are GHRH analogs built on the same 29-amino-acid fragment. Sermorelin is unmodified and clears in roughly 4 minutes [3], so it is dosed nightly. CJC-1295 with DAC carries four substitutions plus a group that binds serum albumin [4], giving an estimated half-life of 5.8 to 8.1 days [1] and allowing weekly dosing.
How long does CJC-1295 stay in your system?
Its estimated half-life is 5.8 to 8.1 days [1]. Functionally the effects last longer than that: a single dose raised mean plasma GH 2 to 10-fold for 6 days or more and IGF-1 1.5 to 3-fold for 9 to 11 days, and with repeated dosing IGF-1 stayed above baseline for up to 28 days [1].
Does CJC-1295 stop natural GH pulsatility?
No, and this is commonly misstated. A study designed to test it found GH pulse frequency and magnitude unchanged one week after dosing. What rose was basal GH, by 7.5-fold, along with mean GH up 46% and IGF-1 up 45% [2]. So pulses persist and the trough between them is elevated. Whether sustained basal elevation matters long-term has not been established in humans.
Is CJC-1295 safer than sermorelin?
The available signals point the other way. FDA states it has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction, and that clinical data are limited [6]; there is no equivalent FDA statement for sermorelin. The only registered CJC-1295 patient trial was terminated in 2006 [5]. No head-to-head safety comparison exists.
What is the difference between CJC-1295 with and without DAC?
DAC is the modification that binds the peptide to serum albumin and produces the multi-day half-life [4]. The version sold without DAC lacks that binding and is much shorter acting, functionally closer to sermorelin. It is often marketed as equivalent to Mod GRF 1-29, which is vendor nomenclature rather than established terminology, and it remains essentially uncharacterized in peer-reviewed human literature with no controlled clinical studies.
Can you take sermorelin and CJC-1295 together?
No published study has evaluated the combination, and there is a mechanistic reason for caution: both act on the same GHRH receptor, so combining them is not additive in the way pairing a GHRH analog with a GHRP is. Any combination protocol should come from a prescribing physician working from your IGF-1 values rather than from a stacking chart.
References
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/
- Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men Journal of Clinical Endocrinology & Metabolism, 1994. PMID: 7962295. https://pubmed.ncbi.nlm.nih.gov/7962295/
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Endocrinology, 2005. PMID: 15817669. https://pubmed.ncbi.nlm.nih.gov/15817669/
- A multicenter, randomized, placebo-controlled, double-blind, phase 2 study to evaluate the efficacy and safety of CJC-1295 administered for 12 weeks in HIV infected patients with HIV associated visceral obesity ClinicalTrials.gov, 2006. NCT00267527, terminated. https://clinicaltrials.gov/study/NCT00267527
- Certain bulk drug substances for use in compounding that may present significant safety risks FDA.gov, Human Drug Compounding, 2026. Content current as of 04/22/2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- The 2026 Prohibited List: International Standard, section S2.2.4 growth hormone releasing factors World Anti-Doping Agency, 2026. WADA 2026 Prohibited List. https://www.wada-ama.org/en/resources/2026-prohibited-list
- Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects Growth Hormone & IGF Research, 2009. PMID: 19386527. https://pubmed.ncbi.nlm.nih.gov/19386527/
